Investor Presentation. The written and oral communications made by the Company in connection with its investor presentation of September 2015 in connection with the offering of the Notes (the “Investor Presentation”) did not include any material non-public information, did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances in which they were made, not misleading, and did not constitute an offering of the Notes.
Investor Presentation. The information and statements contained in the investor presentation dated February 2018 (the “Investor Presentation”) as prepared by the Corporation, and this Agreement, with respect to the Corporation are true and correct and do not (i) contain any untrue statement of a material fact in respect of the Corporation or the affairs, prospects, operations or condition of the Corporation, or any of its assets; or (ii) to the knowledge of the Corporation, omit any statement of a material fact necessary in order to make the statements in respect of the Corporation, the affairs, prospects, operations or condition of the Corporation or its assets contained herein or therein not misleading. There is no fact known to the Corporation which materially and adversely affects the affairs, prospects, operations or condition of the Corporation or any of its assets which has not been set forth in this Agreement. All forward-looking information and statements of the Corporation contained in the Investor Presentation and the assumptions underlying such information and statements, subject to any qualifications contained therein, are to the knowledge of the Corporation, reasonable in the circumstances as at the date on which such assumptions were made.
Investor Presentation. The investor presentation dated August 2017 (the “Investor Presentation”) provided to the Purchaser pertaining to the proposed financial terms of Community First Acquisition does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they are made, subject to the forward-looking statements disclaimer and risks described therein.
Investor Presentation. A link to the company’s investor presentation can be found at xxxxx://xxx.xxxxxxxxxxxxxxxxxxxx.xxx/xxxxxxxxx-3-investor-presentation. Advisors Citigroup is serving as the private placement agent and capital markets advisor to Xxxxxxxxx. Citigroup and Xxxxxxx Xxxxx served as financial advisors and Weil, Gotshal & Xxxxxx LLP served as legal counsel to Xxxxxxxxx. Credit Suisse served as a capital markets advisor to Xxxxxxxxx. Citigroup and Xxxxxxx Xxxxx were joint book running managers for Xxxxxxxxx Capital Corp III. Centerview Partners, Barclays, BofA Securities and UBS Investment Bank served as financial advisors to MultiPlan. Xxxxxxxx & Xxxxx and Xxxxxxx Xxxxxxx & Xxxxxxxx served as legal counsel to MultiPlan and H&F. About MultiPlan MultiPlan is committed to helping healthcare payers manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics, and a team rich with industry experience, MultiPlan interprets clients’ needs and customizes innovative solutions that combine its payment integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payers in the commercial health, dental, government and property and casualty markets, and saves these companies approximately $19 billion annually. MultiPlan is owned by Xxxxxxx & Xxxxxxxx and other investors. For more information, visit xxxxxxxxx.xxx. About Xxxxxxxxx Capital Corp III Xxxxxxxxx Capital Corp III is a public investment vehicle formed for the purpose of effecting a merger, acquisition, or similar business combination. Xxxxxxxxx XXX was founded by a group of leading current and former business and financial leaders. Xxxxxxxxx III’s securities are traded on the New York Stock Exchange under ticker symbols CCXX, CCXX WS and CCXX.U. The Company raised $1.1 billion of cash proceeds in an initial public offering in February 2020. Xxxxxxxxx’x first public equity investment company, Xxxxxxxxx Capital Corp, led by Xxxxx Xxxxx, merged with Clarivate Analytics, a leading provider of comprehensive intellectual property and scientific information, analytical tools, and services in May 2019. Xxxxxxxxx Capital Corp II is actively pursuing an initial business combination target in any business or industry. For more information, visit xxx.xxxxxxxxxxxxxxxxxxxx.xxx About Xxxxxxx & Xxxxxxxx Xxxxxxx & Xxxxxxxx (H&F) is a preeminent global private equity firm with a distinctive investment approach focused...
Investor Presentation. The Investor Presentation did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
Investor Presentation. See attached Accretive Consolidation of Alliance and Aux Sable Expanding Pembina’s Premier Natural Gas and NGL Value Chain December 13, 2023 TSX: PPL; NYSE: PBA Advisories A final base shelf prospectus of Pembina Pipeline Corporation (“Pembina” or the “Company”) dated December 13, 2023 (the “final base shelf prospectus”) containing important information relating to the securities described in this presentation has been filed with the securities regulatory authorities in each of the provinces of Canada. A copy of the final base shelf prospectus, any amendment to the final base shelf prospectus and any applicable shelf prospectus supplement that has been filed, is required to be delivered with this presentation. This presentation does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final base shelf prospectus, any amendment and any applicable shelf prospectus supplement for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision. The Company has filed a registration statement on Form F-10 (including the base shelf prospectus) and a preliminary prospectus supplement with the United States Securities and Exchange Commission (the “SEC”) for the offering to which this document relates. This document does not provide full disclosure of all material facts relating to the securities offered. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and the other documents that the Company has filed with the SEC for more complete information about the issuer and the offering, especially risk factors relating to the securities offered. You may obtain these documents free of charge by visiting the SEC’s website at xxxx://xxx.xxx.xxx. Alternatively, the Company, any underwriter, or any dealer participating in the offering will arrange to send you the prospectus (as supplemented by the prospectus supplement) if you request it. Copies of the base shelf prospectus, registration statement on Form F-10, and the applicable prospectus supplements may be obtained upon request in Canada by contacting TD Securities Inc. at 0000 Xxxx Xxxxxx, Xxxxxxxxxxx XX X0X 0X0 Attention: Symcor, NPM, or by telephone at (000) 000-0000 or by email at xxxxxxxxxxx@xx.xxx, RBC Dominion Securities Inc., 000 Xxxxxxxxxx Xxxxxx Xxxx, 0xx Xxxxx, Xxxxxxx, XX X0X 0X0, Attention: Distribution Centre, Phone: (000) 0...
Investor Presentation. The investor presentation dated September 13, 2017 (the “Investor Presentation”) provided to the Purchaser pertaining to the offering and sale of Shares hereunder, the Company and the Minden Acquisition does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they are made, subject to the forward-looking statements disclaimer and risks described therein.
Investor Presentation. The investor presentation dated July 30, 2018 – August 3, 2018 (the “Investor Presentation”) made available to the Purchasers, does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they are made, subject to the forward-looking statements disclaimer described therein.
Investor Presentation. The investor presentation dated May 19, 2017 (the “Investor Presentation”) provided to the Purchaser pertaining to the proposed financial terms of the merger with Xxxxxxx XX, Inc., Xxxxxxx Bank and Trust, American City Bank and Xxxxx X. Xxxxxxx does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained therein not misleading in light of the circumstances in which they are made, subject to the forward-looking statements disclaimer and risks described therein.
Investor Presentation. CEO Dr Xxx Xxxxx, CBO Xx Xxxxx Xxxxxxx and CFO Xxxxxxx Xxxxxxx will provide a live presentation about the terms and rationale for the licensing deal with Stalicla via the Investor Meet Company platform on 12th Oct 2022 at 1:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre‐event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet EVGEN PHARMA PLC via: xxxxx://xxx.xxxxxxxxxxxxxxxxxxx.xxx/evgen‐pharma‐plc/register‐investor. Investors who already follow EVGEN PHARMA PLC on the Investor Meet Company platform will automatically be invited. Enquiries: Evgen Pharma plc Dr Xxx Xxxxx, CEO Xxxxxxx Xxxxxxx, CFO Tel: +00 0000 000000 FinnCap (Nominated Advisor and Broker) Xxxxx Xxxx / Xxxxx Xxxxxx (Corporate Finance) Tel: +00 00 0000 0000 Xxxxx Xxxx/Xxxxx Xxxxx/Xxxxxxx Xxxx (ECM) Instinctif Partners Xxxxxxx Xxxxx‐Xxxxxx / Xxxx Xxxxxx / Xxxxx Xxxxxxxx / Xxxx Xxxxxx Tel: +00 000 000 0000 Xxxxx@Xxxxxxxxxx.xxx Notes to Editors About Evgen Pharma plc Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The Company's lead asset, SFX‐01, is a patented composition of synthetic sulforaphane and alpha‐ cyclodextrin and has completed, with a positive outcome, a Phase 2a clinical trial for oestrogen‐positive (ER+) metastatic breast cancer. In September 2021 the FDA granted Orphan Drug status to SFX‐01 in malignant glioma. The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and AsiaPac as part of the continuing strategy to build the data set of safety and efficacy around the compound. With respect to non‐core areas, Evgen signed an outlicensing deal with JuvLife, the dietary products and functional foods division of Juvenescence Ltd, for the development of a naturally‐sourced sulforaphane nutritional health supplement, stabilised using Evgen's Sulforadex® technology. The Company has its headquarters and registered office at Alderley Park, Cheshire. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. For fu...
